MedTrace Logo

Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy

NCT01186263 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-09-04

No results posted yet for this study

Summary

The purpose of this study is to assess the predictive value of 99mTechnetium (Tc)- labeled albumin in macroaggregates (MAA) and in microspheres (B20) injected into the common hepatic artery for the distribution of 90Yttrium- Selective Internal Radiotherapy (SIRT)-spheres (SIR- spheres).

Conditions

Interventions

DRUG

MAA for diagnostic SPECT imaging

Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.

DRUG

Diagnostic B20- SPECT imaging.

Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.

Sponsors & Collaborators

  • Sirtex Medical

    collaborator INDUSTRY

  • University of Magdeburg

    lead OTHER

Principal Investigators

  • Jens Ricke, Prof. Dr. · University of Magdeburg, Faculty for Medicine

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-07-31
Completion
2013-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01186263 on ClinicalTrials.gov